Aurobindo Pharma's Q3 FY 2025-26 Quarterly Results
- 10 Feb 2026
Result Summary
- Aurobindo Pharma Ltd reported a 5.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.6%.
- Its expenses for the quarter were up by 4.2% QoQ and 7.1% YoY.
- The net profit increased 34.1% QoQ and increased 34.5% YoY.
- The earnings per share (EPS) of Aurobindo Pharma Ltd stood at 15.67 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 8833.54 | 8406.29 | 8135.81 | 5.1% | 8.6% |
Total Expenses | 7430.06 | 7132.03 | 6937.55 | 4.2% | 7.1% |
Profit Before Tax | 1338.15 | 1274.26 | 1198.26 | 5.0% | 11.7% |
Tax | 428.72 | 427.79 | 354.28 | 0.2% | 21.0% |
Profit After Tax | 1137.53 | 848.13 | 845.57 | 34.1% | 34.5% |
Earnings Per Share | 15.67 | 14.61 | 14.56 | 7.3% | 7.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Aurobindo Pharma Ltd is a leading pharmaceutical company based in India, known for its wide range of generic pharmaceuticals and active pharmaceutical ingredients (APIs). The company operates in the healthcare industry, focusing on producing and marketing generic medications, which are crucial for healthcare systems worldwide. Aurobindo Pharma has a strong presence in both the domestic and international markets, with a diversified portfolio that spans several therapeutic areas including antibiotics, anti-retroviral, cardiovascular, central nervous system, gastroenterological, and anti-allergic medications. Recent major developments for Aurobindo Pharma may include regulatory approvals, expansions into new markets, or strategic partnerships, but specific details are not available in the provided data.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Aurobindo Pharma Ltd reported a total income of ₹8,833.54 crores. This represents a quarter-over-quarter (QoQ) increase of 5.1% compared to ₹8,406.29 crores in the second quarter of FY26 (Q2FY26). Additionally, the year-over-year (YoY) growth from the third quarter of the fiscal year 2025 (Q3FY25) was noted at 8.6%, with the previous year's third-quarter total income being ₹8,135.81 crores. This growth in revenue reflects the company's ability to enhance its market position and potentially expand its product offerings or market reach during this period.
Profitability
Aurobindo Pharma Ltd's profitability in Q3FY26 was marked by a profit before tax of ₹1,338.15 crores, showing a QoQ increase of 5.0% from ₹1,274.26 crores in Q2FY26 and a YoY increase of 11.7% from ₹1,198.26 crores in Q3FY25. The company's tax expenses for Q3FY26 amounted to ₹428.72 crores, which remained relatively stable with a minimal QoQ increase of 0.2% from ₹427.79 crores in Q2FY26, but showed a significant YoY increase of 21.0% from ₹354.28 crores in Q3FY25. The profit after tax for Q3FY26 was ₹1,137.53 crores, which translates to a substantial QoQ growth of 34.1% from ₹848.13 crores in Q2FY26 and a YoY increase of 34.5% from ₹845.57 crores in Q3FY25. Earnings per share for Q3FY26 stood at ₹15.67, reflecting a QoQ growth of 7.3% and a YoY growth of 7.6%.
Operating Metrics
The financial data for Q3FY26 reveals that Aurobindo Pharma Ltd's total expenses were ₹7,430.06 crores, marking a 4.2% QoQ increase from ₹7,132.03 crores in Q2FY26 and a 7.1% YoY increase from ₹6,937.55 crores in Q3FY25. This increase in expenses aligns with the company's revenue growth during the period. The company's operational efficiency and cost management strategies can be observed through these figures, indicating how it navigates the balance between income generation and expense management. Additionally, the consistent increase in earnings per share suggests a positive trend in shareholder value, reflecting the company's overall financial health and performance in the period under consideration.